Navigation Links
Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

WESTMINSTER, Colo., Jan. 29 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that members of the Company's senior management will present a corporate overview at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York.

The Company's presentation will take place at 11:00 a.m. (Eastern) on Tuesday, February 5, 2008. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations section. The webcast will be available for replay on Allos' website through February 22, 2008.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or SPA process. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkins lymphoma (NHL). For additional information, please visit the Company's website at

SOURCE Allos Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
3. Allos Therapeutics to Present at the 2007 JMP Securities Healthcare Focus Conference
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... One of the major limitations ... inadequate vascular supply. Nutrient and gas transport throughout ... critical for successful regeneration and integration into the ... in vascularization and promote angiogenesis in a variety ... design and architecture, and enhancing scaffolds with stem ...
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... InterWest Partners,announced today the appointment of ... firm,s Advisory Committee: Caltech,president Dr. Jean-Lou Chameau, ... commissioner Dr. Mark McClellan. The three will ... strategic guidance,to the firm and its portfolio ...
... S. Young awarded "Most Innovative" award by the Association of ... ... Research Inc. (TSX:,ARI), a biotechnology company discovering and developing the ... Young, President,and Chief Executive Officer, received the "Most Innovative" award ...
... to dramatically reduce their dose of these often harsh ... Medicine in St. Louis have taken a step closer ... drug directly on tumors in rabbits using drug-coated nanoparticles. ... than used previously for this purpose markedly slowed tumor ...
Cached Biology Technology:Prestigious Scientific Leaders Join InterWest Advisory Committee 2Prestigious Scientific Leaders Join InterWest Advisory Committee 3Prestigious Scientific Leaders Join InterWest Advisory Committee 4ARIUS recognized for entrepreneurial excellence 2Nanosized technology has supersized effect on tumors 2Nanosized technology has supersized effect on tumors 3
(Date:8/20/2014)... During the past few years, Virginia Tech,s Wu Feng ... Microsoft grant from the "Computing in the Cloud" program, ... a $6 million award from the Air Force on ... from NSF and the National Institutes of Health on ... wove together the "parallel computing" aspects from each grant, ...
(Date:8/20/2014)... of honeybees grows to about 4,000 members, it triggers ... building of a special type of comb used for ... from the Department of Neurobiology and Behaviour at Cornell ... reproductive cycle of honeybee colonies. The results are published ... Nature . , Reproduction isn,t always a honeybee ...
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... an inherited structural mechanism that can make drugs ... mechanism decreases a protein and in turn causes ... therapies are used to treat patients with childhood ... researchers say their finding advances the field of ...
... may account for many cases of immune deficiency, in ... and Common Variable Immunodeficiency (CVID), report researchers in the ... to a new diagnostic test for these conditions, which ... unrecognized because of a lack of good tests. , ...
... Broken sewers, flooded industrial plants and dead bodies are all likely ... , But the water - and the muck it is leaving ... as it is unexpected: Toxins common in most urban environments that ... atop the city. , So says a University of Florida professor ...
Cached Biology News:Genomics researchers discover protein deficit that causes drug toxicity 2Protein amplification in melanoma is possible drug target 2Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: ... region encompassing the human, mouse, ... Accession Number: ... Assurance: Routinely evaluated by ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: